Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 14, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

[Waldenström's macroglobulinemia].

S Poulain1, M Wemeau, S Balkaran

  • 1Service d'hématologie-immunologie-cytogénétique, centre hospitalier, CHR, avenue Désandrouin, 59300 Valenciennes, France.

La Revue De Medecine Interne
|April 6, 2010
PubMed
Summary

Waldenström's macroglobulinemia (WM) is an incurable B-cell disorder. New therapeutic agents targeting WM biology are in development, showing promising preclinical and clinical trial results.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Short-term follow-up of anti-MAG neuropathy patients given bendamustine plus rituximab combination therapy.

Revue neurologique·2025
Same author

Chilaiditi's sign or Chilaiditi's syndrome in the emergency department.

BMJ case reports·2025
Same author

Cytogenetics in the management of mature B-cell non-Hodgkin lymphomas: Guidelines from the Groupe Francophone de Cytogénétique Hematologique (GFCH).

Current research in translational medicine·2023
Same author

The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH).

Leukemia·2022
Same author

Copy-number analysis identified new prognostic marker in acute myeloid leukemia.

Leukemia·2016
Same author

Are there any additional mechanisms for haemolysis in HELLP syndrome?

Thrombosis research·2016

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Waldenström's macroglobulinemia (WM) is a rare B-cell malignancy characterized by bone marrow infiltration and IgM monoclonal gammopathy.
  • Current treatments offer limited efficacy, with low complete response rates and short treatment-free survival, highlighting the need for novel therapeutic strategies.

Observation:

  • Existing therapies for WM, including alkylating agents, nucleoside analogues, and rituximab, have limitations.
  • Advances in understanding WM biology have spurred the development of targeted agents like proteasome inhibitors and Akt/mTor inhibitors.

Findings:

  • Preclinical studies and ongoing clinical trials are evaluating novel agents and combination therapies for WM.
  • Emerging treatments, including bortezomib, perifosine, Rad001, and various monoclonal antibodies, show promising results.

More Related Videos

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
11:10

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

Related Experiment Videos

Last Updated: Jun 14, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
11:10

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

Implications:

  • The development of novel therapeutic agents is crucial for improving outcomes in Waldenström's macroglobulinemia.
  • Targeting WM's underlying biology offers a promising avenue for more effective and potentially curative treatments.